GlassScriptPhysician profile
Paul C Pinto
NPI 1790734879
$2,046.69
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2021: $636 · 2022: $907 · 2023: $85.75 · 2024: $51.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.84 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.10 | 2021-2024 | Xifaxan |
| Janssen Biotech, INC. | $233.49 | 2021-2023 | Remicade, Simponi, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $223.27 | 2019-2022 | |
| Gilead Sciences, INC. | $190.92 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $122.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.09 | 2019-2024 | Eohilia |
| Celgene Corporation | $56.30 | 2022 | |
| Ironwood Pharmaceuticals, INC | $40.38 | 2021 | |
| Amgen INC. | $29.49 | 2022-2023 | Amjevita |
| Ardelyx, INC. | $18.80 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.23 | 2019 | |
| Qol Medical, LLC | $13.86 | 2021 | |
| Medtronic, INC. | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.